Table 3.
Univariate and multivariate regression analysis to identify predictors for hepatotoxicity related to erlotinib administration in lung cancer patients
| Characteristics | Unadjusted OR (95% CI) |
Model I | Model II | ||
|---|---|---|---|---|---|
| Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | ||
| Male | 0.598 (0.212–1.688) | 0.251 (0.060–1.048) | 0.266 (0.065–1.084) | ||
| Age ≥ 65 | 2.623 (0.902–7.633) | 3.198 (1.023–9.997)* | 68.7 | 3.540 (1.123–11.164)* | 71.8 |
| BSA ≥ 1.6 | 1.398 (0.460–4.244) | 3.545 (0.787–15.972) | 3.188 (0.723–14.053) | ||
| PPI | 3.528 (0.984–12.651) | 3.529 (0.916–13.595) | |||
| H2 blocker or PPI | 3.083 (1.056–9.000)* | 3.454 (1.114–10.713)* | 71.0 | ||
For model I construction, sex, age, BSA and PPI were included for analysis. For model II construction, sex, age, BSA and H2 blocker or PPI were included for analysis
BSA body surface area, PPI proton pump inhibitor
*P < 0.05